{"id":"ovulation-triggering-with-gnrh-a-rhcg","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal discomfort or bloating"}]},"_chembl":{"chemblId":"CHEMBL2370644","moleculeType":"Protein","molecularWeight":"1253.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GnRH agonist (GnRH-a) initially suppresses endogenous LH surge through receptor desensitization, preventing premature ovulation during controlled ovarian hyperstimulation. Subsequent administration of rhCG mimics the natural LH surge, inducing final meiotic maturation of oocytes and triggering ovulation approximately 34–36 hours after injection, enabling precise timing for oocyte retrieval.","oneSentence":"GnRH agonist priming followed by recombinant human chorionic gonadotropin (rhCG) triggers final oocyte maturation and ovulation in assisted reproductive technology cycles.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:11.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovulation triggering in assisted reproductive technology (ART) cycles, including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI)"}]},"trialDetails":[{"nctId":"NCT02890082","phase":"PHASE2","title":"Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2014-02","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT04989348","phase":"NA","title":"Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol","status":"COMPLETED","sponsor":"Shanghai First Maternity and Infant Hospital","startDate":"2021-08-04","conditions":"IVF","enrollment":240},{"nctId":"NCT04724486","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI","status":"COMPLETED","sponsor":"Damascus University","startDate":"2020-08-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50},{"nctId":"NCT04724343","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.","status":"COMPLETED","sponsor":"Damascus University","startDate":"2019-12-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50},{"nctId":"NCT04727684","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI","status":"COMPLETED","sponsor":"Damascus University","startDate":"2020-08-22","conditions":"In Vitro Fertilization, Infertility, Intracytoplasmic Sperm Injection","enrollment":50},{"nctId":"NCT04727671","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.","status":"COMPLETED","sponsor":"Damascus University","startDate":"2019-12-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50},{"nctId":"NCT04992468","phase":"PHASE4","title":"Dual Trigger for Elective Fertility Preservation","status":"COMPLETED","sponsor":"Fundación Santiago Dexeus Font","startDate":"2021-10-05","conditions":"Infertility","enrollment":136},{"nctId":"NCT04446845","phase":"PHASE4","title":"Double Stimulation Followed by a Fresh Embryo Transfer","status":"COMPLETED","sponsor":"Fundación Santiago Dexeus Font","startDate":"2020-10-30","conditions":"Infertility","enrollment":120},{"nctId":"NCT04071574","phase":"PHASE1, PHASE2","title":"Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility","status":"COMPLETED","sponsor":"Lebanese University","startDate":"2018-02-01","conditions":"Female Infertility, Female Infertility Due to Ovulatory Disorder, Premature Ovarian Failure","enrollment":200},{"nctId":"NCT05778331","phase":"","title":"The Difference Between POSEIDON Group 3 and Group 4 as Regards IVF","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-01-10","conditions":"Infertility, Female, IVF","enrollment":340},{"nctId":"NCT02703584","phase":"PHASE4","title":"Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2016-03","conditions":"Infertility","enrollment":276},{"nctId":"NCT04537078","phase":"PHASE3","title":"Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders","status":"COMPLETED","sponsor":"El Shatby University Hospital for Obstetrics and Gynecology","startDate":"2020-09-01","conditions":"Infertility, Female","enrollment":90},{"nctId":"NCT02431689","phase":"NA","title":"Delayed Embryo Transfer in Poor Responders","status":"COMPLETED","sponsor":"Cairo University","startDate":"2015-04","conditions":"Infertility","enrollment":400},{"nctId":"NCT02381821","phase":"","title":"Endometrial Volume and Sub-endometrial Vascularity as Predictors of In-vitro Fertilization Success","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-01-01","conditions":"Reproductive Techniques, Assisted","enrollment":82},{"nctId":"NCT02827656","phase":"NA","title":"Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2016-08","conditions":"Infertility","enrollment":50},{"nctId":"NCT02813239","phase":"","title":"Dual Triggering in Patients With a High Immature Oocyte Rate","status":"COMPLETED","sponsor":"IVI Madrid","startDate":"2014-11","conditions":"INFERTILITY","enrollment":81},{"nctId":"NCT02640976","phase":"EARLY_PHASE1","title":"Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program","status":"COMPLETED","sponsor":"Cairo University","startDate":"2013-06","conditions":"Infertility","enrollment":216},{"nctId":"NCT01210144","phase":"PHASE4","title":"EXpression PRofile Endometrium Samples Study","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-08","conditions":"In Vitro Fertilization","enrollment":27},{"nctId":"NCT00627406","phase":"PHASE4","title":"Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles","status":"COMPLETED","sponsor":"Regionshospitalet Viborg, Skive","startDate":"2009-01","conditions":"OHSS (Ovarian Hyperstimulation)","enrollment":384}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ovulation triggering with GnRH-a+rhCG","genericName":"Ovulation triggering with GnRH-a+rhCG","companyName":"Fundación Santiago Dexeus Font","companyId":"fundaci-n-santiago-dexeus-font","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GnRH agonist priming followed by recombinant human chorionic gonadotropin (rhCG) triggers final oocyte maturation and ovulation in assisted reproductive technology cycles. Used for Ovulation triggering in assisted reproductive technology (ART) cycles, including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}